Cargando…
P644: IBRUTINIB DOSE MODIFICATIONS FOR MANAGEMENT OF CARDIAC ADVERSE EVENTS IN PATIENTS WITH B-CELL MALIGNANCIES: POOLED ANALYSIS OF 10 CLINICAL TRIALS
Autores principales: | Stephens, Deborah, R. Brown, Jennifer, MA, Shuo, Wang, Michael, Moreno, Carol, Robak, Tadeusz, Stevens, Don, Lee, Shane, Saifan, Chadi, Hsu, Emily, Patel, Sima, Burger, Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429779/ http://dx.doi.org/10.1097/01.HS9.0000969480.41719.97 |
Ejemplares similares
-
P621: REAL-WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT
por: Shadman, Mazyar, et al.
Publicado: (2023) -
Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
por: O'Brien, Susan M., et al.
Publicado: (2019) -
Ibrutinib dose modifications in the management of CLL
por: Hardy-Abeloos, Camille, et al.
Publicado: (2020) -
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
por: Barr, Paul M., et al.
Publicado: (2022) -
Regulation of B family DNA polymerase fidelity by a conserved active site residue: characterization of M644W, M644L and M644F mutants of yeast DNA polymerase ε
por: Pursell, Zachary F., et al.
Publicado: (2007)